SCHEMBL375179

SCHEMBL375179

O=C1c2cccc(NCCCO)c2C(=O)c2c(NCCCO)cccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 2/20 0.70
FGB P02675 1/20 0.70
MMP14 P50281 1/20 0.70
MAPT P10636 6/20 0.68
ALDH1A1 P00352 4/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
LMNA P02545 3/20 0.68
HTT P42858 3/20 0.68
MAPK1 P28482 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
POLB P06746 3/20 0.68
EGFR P00533 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.68
BLM P54132 2/20 0.68
RAD52 P43351 1/20 0.68
RECQL P46063 1/20 0.68
NPSR1 Q6W5P4 1/20 0.68
TERT O14746 4/20 0.67
CYP19A1 P11511 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375063 0.95 NSD2 (0.77) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL6678121 0.94 MAPT (0.77) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL32679354 0.94 MAPT (0.77) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL20333890 0.90 NSD2 (0.69) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL6665263 0.89 MAPT (0.75) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL6661851 0.88 MAPT (0.73) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL9883949 0.88 NSD2 (0.68) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL12658875 0.88 MAPT (0.73) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL31616918 0.88 MAPT (0.73) NSD2FGBMMP14MAPTALDH1A1
SCHEMBL9357997 0.84 NSD2 (0.77) NSD2FGBMMP14MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504495-B2 Quencher compositions comprising anthraquinone moieties EXIQON A/S (DK) 2009-03-17 US claimed
EP-1538154-B1 Quencher composition comprising anthraquinone moieties EXIQON AS (DK) 2008-12-31 EP claimed
EP-1831394-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME Exiqon A/S (DK) 2007-09-12 EP claimed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 US claimed
WO-2006066592-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME EXIQON A/S (DK) 2006-06-29 WO claimed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 US claimed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 EP claimed
US-20240209420-A1 COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES KASA BIO, L.L.C. 2024-06-27 US disclosed
EP-4388133-A2 COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES Kasa Bio, L.L.C. (US) 2024-06-26 EP disclosed
US-11952617-B2 Methods for multiplex detection of polynucleotides using unbound fluorescent probes and quencher oligonucleotides KASA BIO, L.L.C. (US) 2024-04-09 US disclosed
US-20230265490-A1 COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCLEOTIDES KASA BIO, L.L.C. 2023-08-24 US disclosed
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION L'OREAL (FR) 2023-08-03 US disclosed
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION L'OREAL (FR) 2023-08-03 US disclosed
US-20050272075-A1 Novel methods for quantification of microRNAs and small interfering RNAs QIAGEN GMBH (DE) 2005-12-08 US disclosed
WO-2005098029-A2 METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON A/S (DK) 2005-10-20 WO disclosed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 US disclosed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 EP disclosed
US-20030130272-A1 Anthracene derivatives as anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-07-10 US disclosed
EP-1244624-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2002-10-02 EP disclosed
WO-2001044190-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties ANXA5, SUN2, ANXA3 NSD2 3445/4885FGB 2526/4885MMP14 4002/4885
US-20030130272-A1 Anthracene derivatives as anti-cancer agents TOP2B, TOP1, TOP2A NSD2 2181/4885FGB 2378/4885MMP14 3090/4885
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION KRT18, CUTA, KLK5 NSD2 2000/4885FGB 247/4885MMP14 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.